RFK Jr. Forces FDA Peptide Review as Young Men Inject at Epidemic Rate

HHS Secretary Robert F. Kennedy Jr. is pushing the Food and Drug Administration to reverse its 2023 ban on 14 peptides deemed to have significant safety concerns, raising the stakes in a debate that pits regulatory caution against the reality of widespread unregulated use. A new USA Today opinion piece published May 25 captures the tension: a 19-year-old college freshman documents how young men are already injecting peptides at epidemic levels source.

Kennedy told podcaster Joe Rogan in February that the FDA would announce “some kind of new action” on injectable peptides “within a couple of weeks,” calling himself a “big fan of peptides.” He argued that the Biden administration put the substances on a “do not produce” list “illegally,” claiming the ban created a black market. In April, Reuters confirmed the FDA would convene a panel of outside advisers in July to recommend whether to allow licensed compounding pharmacies to manufacture 12 of the 14 peptides — narrowing the original list after several manufacturers challenged the ban in court source.

The compounds under review include BPC-157 and TB-500, two peptides widely used in bodybuilding and recovery circles that PeptidesBeat has previously covered in compound guides.

Young men describe peer-driven injection culture

The USA Today opinion piece, written by Eli Thompson, offers a ground-level view of the peptide phenomenon that regulators rarely see. Thompson describes peptides as a subject of casual conversation among young men at his college: “In gyms, locker rooms and group chats, young men around me are talking about peptides in a way that would have been crazy just a few years ago.”

The column notes that users rarely discuss risks. “They mention faster muscle growth, better recovery and more confidence. They rarely talk about risks,” Thompson writes, citing potential hormone imbalances, organ stress, and the risk of progression to more dangerous substances.

The piece adds a dimension to a growing body of reporting on young male peptide use. The Wall Street Journal reported May 11 that teen boys and young men are injecting peptides “in search of perfection,” and a Sunlight survey from May 25 found that 45% of social-media peptide buyers visited the emergency room read the Sunlight survey coverage.

The gap between deregulation and public health

The FDA’s July PCAC meeting will determine the regulatory trajectory for the 12 peptides still on the review list. The panel will weigh whether compounding pharmacies should be permitted to produce these substances, which would effectively reverse large portions of the 2023 enforcement action.

Public health experts point to a paradox in the timing. The same week Kennedy’s push was reported, the American Medical Association published guidance for physicians on injectable peptides, cautioning that the evidence base for most non-prescription peptides remains thin. ECRI, an independent patient safety organization, issued a white paper on compounded peptide safety warnings that PeptidesBeat covered last week read ECRI coverage.

“Kennedy’s view that deregulation will eliminate the black market assumes that the current gray market exists primarily because of the ban,” said one compounding pharmacy regulatory analyst who spoke on background. “But the evidence suggests demand is being driven by social media, fitness influencers, and a broader cultural shift toward biohacking — not just supply constraints.”

What the July PCAC meeting means

The FDA’s outside advisory panel is expected to meet in mid-July to review the 12 peptides reclassified from Category 2 (significant safety concern) back to Category 1 (enforcement discretion). The original April 2023 enforcement action had placed 14 peptides on Category 2, prohibiting compounding pharmacies from producing them without an individual patient prescription.

The distinction matters for compounders: Category 2 status effectively bans bulk compounding, while Category 1 allows it under the usual 503A/503B framework. A recommendation to return the peptides to Category 1 would represent a significant reversal of the FDA’s position.

GHK-Cu, which was listed in Category 1 from the outset and never faced the same restrictions, is a model for how the reclassified peptides might be handled read the GHK-Cu guide. Its PCAC review is not scheduled until early 2027, reflecting its distinct regulatory history.

What comes next

Kennedy’s push creates unusual pressure on the FDA’s independent review process. While HHS secretaries have historically signaled policy preferences, directly calling for the reversal of a concluded enforcement action is less common. The July PCAC outcome will signal whether the advisory panel treats the Kennedy intervention as direction or as background noise.

For the young men described in the USA Today column, the regulatory outcome may matter less than the culture already in place. As Thompson writes: “The tone is casual. It feels no different than talking about a new workout plan or diet.”

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.